Oneness Biotech Co., Ltd. receives a Chinese patent titled "TREATING IGE-MEDIATED ALLERGIC DISEASES"on FB825.

Published Date:2025-01-17

Original Link:https://www.onenessbio.com/en/news_detail332_3.htm

Statement
No	1	Date of announcement	2025/01/17	Time of announcement	17:39:27
Subject	Oneness Biotech Co., Ltd. receives a Chinese patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES”on FB825.
To which item it meets	paragraph 53			Date of events	2025/01/17
Date of occurrence of the event: 2025/01/17 Company name: ONENESS BIOTECH CO., LTD Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office Reciprocal shareholding ratios: NA Cause of occurrence: The Company has been informed by the patent agency that a Chinese patent titled ”TREATING IGE-MEDIATED ALLERGIC DISEASES” has been granted on humanized anti-CεmX monoclonal antibody (FB825) under the patent number ZL 2018 8 0084604.5. Countermeasures: None Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): This patent expanded our patent protection to cover indications related to IgE-mediated allergic diseases as well as long-acting treatment regimen. This patent strategy will create barriers to entry and enhance the opportunities for maximizing patent protection for FB825. The patent applications have been filed in the countries or regions with large healthcare spending, ensuring protection until 2038. If approved for commercialization in China in the future, a patent term extension of up to 5 years can be requested, making it an important patent for FB825.